Serum sCD95L concentration in patients with spinal cord injury

J Int Med Res. 2015 Apr;43(2):250-6. doi: 10.1177/0300060514559794. Epub 2015 Jan 19.

Abstract

Objective: To determine serum concentrations of soluble CD95 ligand (sCD95L) in patients with traumatic spinal cord injury.

Methods: Patients with traumatic spinal cord injury were recruited. Blood was collected on admission to hospital and at 4 h, 9 h, 12 h, 24 h, 3 days, 7 days, and 2, 4, 8 and 12 weeks postadmission. Serum concentrations of sCD95L were determined via immunoassay.

Result: The study included 23 patients. Mean sCD95L concentrations were significantly lower at 4 h, 9 h, 12 h and 24 h than at admission, and were significantly higher at 8 and 12 weeks, compared with admission.

Conclusion: The serum sCD95L concentration fell significantly during the first 24 h after traumatic spinal cord injury. Concentrations then rose, becoming significantly higher than admission levels at 8 weeks. sCD95L may represent a possible therapeutic target for traumatic spinal cord injury.

Keywords: CD95 ligand; Spinal cord injury; neurological remission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • Cohort Studies
  • Double-Blind Method
  • Fas Ligand Protein / blood*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Spinal Cord Injuries / blood*
  • Young Adult

Substances

  • Biomarkers
  • Fas Ligand Protein